Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

Gerlier L, Lamotte M, Mendes SDS, Damm O, Schwehm M, Eichner M (2016)
PEDIATRIC DRUGS 18(4): 303-318.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ;
Abstract / Bemerkung
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
Erscheinungsjahr
Zeitschriftentitel
PEDIATRIC DRUGS
Band
18
Zeitschriftennummer
4
Seite
303-318
ISSN
eISSN
PUB-ID

Zitieren

Gerlier L, Lamotte M, Mendes SDS, Damm O, Schwehm M, Eichner M. Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. PEDIATRIC DRUGS. 2016;18(4):303-318.
Gerlier, L., Lamotte, M., Mendes, S. D. S., Damm, O., Schwehm, M., & Eichner, M. (2016). Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. PEDIATRIC DRUGS, 18(4), 303-318. doi:10.1007/s40272-016-0180-6
Gerlier, L., Lamotte, M., Mendes, S. D. S., Damm, O., Schwehm, M., and Eichner, M. (2016). Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. PEDIATRIC DRUGS 18, 303-318.
Gerlier, L., et al., 2016. Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. PEDIATRIC DRUGS, 18(4), p 303-318.
L. Gerlier, et al., “Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium”, PEDIATRIC DRUGS, vol. 18, 2016, pp. 303-318.
Gerlier, L., Lamotte, M., Mendes, S.D.S., Damm, O., Schwehm, M., Eichner, M.: Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. PEDIATRIC DRUGS. 18, 303-318 (2016).
Gerlier, Laetitia, Lamotte, Mark, Mendes, Sofia Dos Santos, Damm, Oliver, Schwehm, Markus, and Eichner, Martin. “Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium”. PEDIATRIC DRUGS 18.4 (2016): 303-318.

4 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
Gerlier L, Lamotte M, Grenèche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M., Appl Health Econ Health Policy 15(2), 2017
PMID: 27943165
Direct and indirect effects of influenza vaccination.
Eichner M, Schwehm M, Eichner L, Gerlier L., BMC Infect Dis 17(1), 2017
PMID: 28441935
A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.
Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R., Hum Vaccin Immunother 13(7), 2017
PMID: 28532276
Epidemiological factors related to hospitalization due to influenza in children below 6 months of age.
Bustamante J, Calzado I, Sainz T, Calvo C, Del Rosal T, Méndez-Echevarría A., Eur J Pediatr 176(10), 2017
PMID: 28852864

67 References

Daten bereitgestellt von Europe PubMed Central.

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.
McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J., J Prim Prev 36(4), 2015
PMID: 26032932
Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study.
Crott R, Pouplier I, Roch I, Chen YC, Closon MC., Arch Public Health 72(1), 2014
PMID: 25705380
Economic burden of seasonal influenza B in France during winter 2010-2011.
Silva ML, Perrier L, Spath HM, Grog I, Mosnier A, Havet N, Cohen JM; IBGP team., BMC Public Health 14(), 2014
PMID: 24443900
The disease burden of hepatitis B, influenza, measles and salmonellosis in Germany: first results of the burden of communicable diseases in Europe study.
Plass D, Mangen MJ, Kraemer A, Pinheiro P, Gilsdorf A, Krause G, Gibbons CL, VAN Lier A, McDONALD SA, Brooke RJ, Kramarz P, Cassini A, Kretzschmar ME., Epidemiol. Infect. 142(10), 2014
PMID: 24480146
The impact of influenza-like illness in young children on their parents: a quality of life survey.
Chow MY, Yin JK, Heron L, Morrow A, Dierig A, Booy R, Leask J., Qual Life Res 23(5), 2013
PMID: 24370954
Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients.
Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J., PLoS ONE 8(3), 2013
PMID: 23555979
Burden of paediatric influenza in Western Europe: a systematic review.
Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N., BMC Public Health 12(), 2012
PMID: 23146107
Global burden of influenza as a cause of cardiopulmonary morbidity and mortality.
Fischer WA 2nd, Gong M, Bhagwanjee S, Sevransky J., Glob Heart 9(3), 2014
PMID: 25667184

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Influenza A and B virus infections in children.
Peltola V, Ziegler T, Ruuskanen O., Clin. Infect. Dis. 36(3), 2003
PMID: 12539071
The burden of influenza in young children, 2004-2009.
Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, Snively BM, Suerken CK, Hall CB, Weinberg GA, Chaves SS, Zhu Y, McNeal MM, Bridges CB., Pediatrics 131(2), 2013
PMID: 23296444
Fatal cases of influenza a in childhood.
Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, McMenamin J, Fleming DM, Zambon MC., PLoS ONE 4(10), 2009
PMID: 19876396
Influenza-associated pediatric deaths in the United States, 2004-2012.
Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, Finelli L., Pediatrics 132(5), 2013
PMID: 24167165

AUTHOR UNKNOWN, 0
Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies.
Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, Schunemann HJ., Influenza Other Respir Viruses 7 Suppl 2(), 2013
PMID: 24034489
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.
Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S., PLoS ONE 8(4), 2013
PMID: 23565231

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15.
Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, Ellis J, Steinberger S, Donati M, Elliot AJ, Hughes HE, Pathirannehelage S, Mullett D, Smith GE, de Lusignan S, Zambon M., Euro Surveill. 20(39), 2015
PMID: 26537222

AUTHOR UNKNOWN, 0
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, Aoki F, Horsman G, Van Caeseele P, Chokani K, Vooght M, Babiuk L, Webby R, Walter SD., JAMA 303(10), 2010
PMID: 20215608
Population-wide benefits of routine vaccination of children against influenza.
Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G., Vaccine 23(10), 2005
PMID: 15652671
Estimating the impact of childhood influenza vaccination programmes in England and Wales.
Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ., Vaccine 26(41), 2008
PMID: 18647634
Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.
Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999132
Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study.
Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ., PLoS Med. 10(10), 2013
PMID: 24115913
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.
Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Kruger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, Eichner M., BMC Infect. Dis. 14(), 2014
PMID: 24450996
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Kruger H, Greiner W., Eur J Health Econ 16(5), 2014
PMID: 24859492
Public Health and Economic Impact of Vaccinating Children with a Quadrivalent live Attenuated Influenza Vaccine in France Using a Dynamic Transmission Model.
Gerlier L, Weil-Olivier C, Carrat F, Lenne X, Lamotte M, Greneche S, Eichner M., Value Health 17(7), 2014
PMID: 27202479

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Social contacts and mixing patterns relevant to the spread of infectious diseases.
Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ., PLoS Med. 5(3), 2008
PMID: 18366252
Time lines of infection and disease in human influenza: a review of volunteer challenge studies.
Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ., Am. J. Epidemiol. 167(7), 2008
PMID: 18230677
Oral oseltamivir treatment of influenza in children.
Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P., Pediatr. Infect. Dis. J. 20(2), 2001
PMID: 11224828
Burden of influenza in children in the community.
Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T., J. Infect. Dis. 190(8), 2004
PMID: 15378427

AUTHOR UNKNOWN, 0
Vaccines for preventing influenza in healthy children.
Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V., Cochrane Database Syst Rev (2), 2008
PMID: 18425905
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J., Vaccine 27(7), 2008
PMID: 19095024
Comparative efficacy of inactivated and live attenuated influenza vaccines.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC., N. Engl. J. Med. 361(13), 2009
PMID: 19776407
Vaccines for preventing influenza in the elderly.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE., Cochrane Database Syst Rev (2), 2010
PMID: 20166072
Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.
Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ., Vaccine 33(1), 2014
PMID: 24962752
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network., Pediatr. Infect. Dis. J. 26(7), 2007
PMID: 17596805

AUTHOR UNKNOWN, 0
Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years.
Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA., Arch Pediatr Adolesc Med 165(2), 2010
PMID: 20921341

AUTHOR UNKNOWN, 0
Children's perceptions of influenza illness and preferences for influenza vaccine.
Flood EM, Block SL, Hall MC, Rousculp MD, Divino VM, Toback SL, Mahadevia PJ., J Pediatr Health Care 25(3), 2010
PMID: 21514492
Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial.
Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, Hamid JS, Feinberg Y, Winter AL, Gubbay JB, Sirtonski B, Moher D, Sider D, Finkelstein M, Loeb M; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group., Vaccine 33(4), 2014
PMID: 25488331

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
[Taking charge of influenza in the context of a pandemic situation 2005. Short text].
Groupe de Travail., Med Mal Infect 35 Suppl 4(), 2005
PMID: 16535782
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R., N. Engl. J. Med. 365(15), 2011
PMID: 21995388
Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.
Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H., Eur. J. Clin. Microbiol. Infect. Dis. 19(11), 2000
PMID: 11152308

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 27272706
PubMed | Europe PMC

Suchen in

Google Scholar